Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients
Open-Label, Single-Centre, Randomised Pilot Study to Evaluate Immunovirological and Clinical Evolution of a Combination With Nucleoside Analogues/Nucleotides (Trizivir +Tenofovir) in Multiresistant Patients With Virological Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- H.U. Germans Trias i Pujol
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age>= 18 years.
- HIV-1 infected patients.
- Patients on antiretroviral treatment including NTRI + PI +/- NNRTI +/- fusion inhibitors at inclusion in the study.
- Virological failure, defined as 2 determinations with viral load >1,000 copies/mL in the last 6 months, during stable HAART therapy over the previous 6 months.
Genotype or phenotype resistance to three families of antiretrovirals (PI, NTRI and NNRTI) demonstrated in genotype study carried out in the last 48 weeks and defined as:
- 3 or more TAMS of the following: M41L, E44D, D67N, V118I, L210W, T215Y/F, K219Q/E.
- Existence of the M184V mutation or probable presence in the cellular archives.
- 5 or more mutations that confer resistance to PI of the following: I10F/I/R/V, V32I, M46I/L, I54V/M/L, V82A/F/T/S/V, I84V/A/C, L90M.
- Existence of 1 or more mutations that confer resistance to NNRTI, or probable presence in the cellular archives of: K103N, Y181C/I/Y, G190S/A/G.
- CD4 lymphocytes >- 300 cells/mm3 in the last two determinations.
- Subject able to follow the treatment period.
- Acceptance of the study and signature of the informed consent form.
- Women may not be of fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or must undertake to use a barrier contraceptive method during the study.
Exclusion Criteria:
- Suspicion of previous incorrect adherence.
- Pregnancy or breastfeeding
- Suspicion of intolerance to any investigational drug.
- Record of any disease which, according to clinical criteria, may reoccur with the proposed change of therapy (sarcoma, lymphoma, etc).
- CD4 Nadir below 200 cel/mm3.
- Acute intercurrent disease or fever in the 15 days before inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: A
Trizivir+ Tenofovir 2/day
|
Trizivir (AZT+3HT+Abacavir) twice daily
Viread (300 mg Tenofovir disoproxil fumarate) once daily
|
|
No Intervention: B
antiretroviral treatment optimizated by genotyp
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Variations in the immune status of patients in each group throughout follow-up.
Time Frame: 48 weeks
|
48 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of patients that increase viral load by > 0.5 log
Time Frame: weeks 12, 24, 36 and 48
|
weeks 12, 24, 36 and 48
|
|
Percentage of patients that increase viral load by > 100,000 copies/mL
Time Frame: weeks 12, 24, 36 and 48
|
weeks 12, 24, 36 and 48
|
|
Percentage of patients that present some clinical event, B or C classification according to the CDC.
Time Frame: during the 48 weeks of follow-up
|
during the 48 weeks of follow-up
|
|
Percentage of patients that present clinical or analytical adverse effects degree > 2 according to the WHO classification.
Time Frame: weeks 12, 24, 36 and 48
|
weeks 12, 24, 36 and 48
|
|
Percentage of patients that drop out of treatment.
Time Frame: weeks 12, 24, 36 and 48
|
weeks 12, 24, 36 and 48
|
|
Percentage of patients that drop out of the study due to intolerance or adverse effects.
Time Frame: weeks 12, 24, 36 and 48
|
weeks 12, 24, 36 and 48
|
|
Percentage of change in lipid determinations.
Time Frame: weeks 12, 24, 36 and 48 with regard to baseline
|
weeks 12, 24, 36 and 48 with regard to baseline
|
|
Percentage of patients that report changes, improvement or worsening in redistribution of body fat.
Time Frame: weeks 12, 24, 36 and 48
|
weeks 12, 24, 36 and 48
|
|
Percentage of patients that present adherence to the antiretroviral treatment > 95%.
Time Frame: weeks 12, 24, 36 and 48
|
weeks 12, 24, 36 and 48
|
|
Percentage of patients that present improvement in the quality of life (MOS-HIV) and satisfaction questionnaires.
Time Frame: weeks 12, 24, 36 and 48
|
weeks 12, 24, 36 and 48
|
|
Percentage of patients that present an increase in the number of active drugs.
Time Frame: at the end of the study
|
at the end of the study
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
- Abacavir
Other Study ID Numbers
Other Study ID Numbers
- TETRIZ
- 2005-002203-17
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.